Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

Cancer Res. 2015 Sep 1;75(17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139.

Abstract

Many tumors overexpress tumor-associated antigens relative to normal tissue, such as EGFR. This limits targeting by human T cells modified to express chimeric antigen receptors (CAR) due to potential for deleterious recognition of normal cells. We sought to generate CAR(+) T cells capable of distinguishing malignant from normal cells based on the disparate density of EGFR expression by generating two CARs from monoclonal antibodies that differ in affinity. T cells with low-affinity nimotuzumab-CAR selectively targeted cells overexpressing EGFR, but exhibited diminished effector function as the density of EGFR decreased. In contrast, the activation of T cells bearing high-affinity cetuximab-CAR was not affected by the density of EGFR. In summary, we describe the generation of CARs able to tune T-cell activity to the level of EGFR expression in which a CAR with reduced affinity enabled T cells to distinguish malignant from nonmalignant cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antigens, Neoplasm / immunology*
  • Cell Line, Tumor
  • Cetuximab / administration & dosage
  • Epitopes / immunology
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / biosynthesis
  • ErbB Receptors / immunology*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunotherapy, Adoptive
  • Mice
  • Neoplasms / drug therapy
  • Neoplasms / genetics
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Receptors, Antigen / immunology*
  • Receptors, Antigen / therapeutic use
  • Signal Transduction
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / pathology
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, Neoplasm
  • Epitopes
  • Receptors, Antigen
  • nimotuzumab
  • EGFR protein, human
  • ErbB Receptors
  • Cetuximab